Ingo Hartung

ESTP Congress
,

Ingo Hartung is a synthetic organic chemist by training (PhD University of Hannover/Germany, Postdoc Stanford University/US) with more than 15 years of Pharma industry experience (Schering AG, Bayer AG, Merck KGaA). He has been project leader in oncology and cardiology NCE drug discovery and has had portfolio responsibility for preclinical research in the areas of epigenetics and immuno-oncology. In addition to his current role as head of Merck’s Medicinal Chemistry & Drug Design department, Ingo is leading Merck’s global cross-functional targeted protein degradation platform. His research interests comprise all aspects of innovation in small molecule drug discovery with a special focus on new synthetic modalities like protein degraders. Ingo Hartung is a member of the Steering Committee of the Chemistry in Cancer Research Working Group of the AACR and Advisor to the President of the European Federation of Medicinal Chemistry. He is the author of >50 scientific publications and patents.